Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader, has been named senior vice president and chief quality and regulatory affairs officer. Adrienne Brott has joined Quest Diagnostics as Senior Vice President and Chief Quality a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Quest Diagnostics (DGX) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider.When looking at the last two reports, this medical laboratory operator has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 1.75%, on average, in the last two quarte ...

Quest Diagnostics Inc. (DGX) has availed a personalized, one-on-one health coaching service on questhealth.com, through its subsidiary, Pack Health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.For a more customised experience, individuals can pair their Quest lab work with their health coaching to put their diagnostic insights into action.Predicting DGX Stock Movement Following the NewsAfter the a ...

文章核心观点 - Quest Health推出个性化一对一健康教练服务，结合Quest实验室结果，帮助个人实现健康目标 [1][2] 服务介绍 - 服务由Pack Health提供，是Quest Diagnostics的子公司，专注于基于证据的患者参与服务 [1] - 服务包括与持牌健康顾问的一对一支持、资源和教育，专注于个人独特的健康目标 [1] - 服务涵盖多个关键领域，包括一般健康、体重管理、慢性肾病、2型糖尿病和高胆固醇 [1] - 个人可以选择将Quest实验室工作与健康教练配对，以将诊断见解转化为行动 [1] 市场背景 - 60%的美国人表示他们想要健康教练，但大多数从未从医疗提供者或雇主那里获得过该服务 [2] - 消费者在购买健康产品时，功效是最重要的考虑因素，近五分之一的美国消费者更喜欢个性化产品和服务的 [1] 服务特点 - 提供4次和6次会话的套餐，价格分别为225美元和275美元 [2] - 每个套餐包括： - 专属健康顾问，通过30分钟的虚拟教练会话提供一对一支持 [2] - 健康顾问定期发送短信和电子邮件，帮助个人保持进度并朝着他们的独特健康目标前进 [2] - 欢迎包，包括培训手册、拉伸带和额外的健康资源 [2] - 每周学习模块和信息文章和视频的精选数字内容 [2] - 个人可以选择与健康顾问分享最近的实验室测试结果，这有助于提供关于可预防疾病的宝贵见解 [2] 服务购买 - 感兴趣的个人可以访问questhealth.com购买服务并配对个人健康教练 [2] 公司背景 - Quest Health是Quest Diagnostics的子公司，提供消费者发起的测试平台，使消费者能够控制自己的健康旅程 [4] - Quest Diagnostics通过其实验室测试提供诊断见解，帮助人们、医生和组织采取行动改善健康结果 [6] - Quest Diagnostics每年为三分之一的美国成年人和美国一半的医生和医院提供服务 [6]

公司Q3财报业绩 - 2024年第三季度调整后每股收益为2.30美元较Zacks共识预期高出1.8%较去年调整后数字高出3.6% [2] - GAAP每股收益为1.99美元较去年同期增长1.5% [3] - 第三季度营收同比增长8.4%达24.9亿美元较Zacks共识预期高出3.4% [4] - 诊断信息服务（DIS）季度营收同比增长8.9%达24.3亿美元超过模型对第三季度23.1亿美元的预测 [4] - 第三季度按申请数量衡量的业务量同比增长5.5%每份申请收入同比增长3.3% [5] - 报告季度服务成本为16.8亿美元同比增长8.8%毛利润为8.11亿美元同比增长7.6%但毛利率为32.6%较去年同期收缩26个基点 [6] - 本季度销售总务管理（SG&A）费用为4.48亿美元较2023年第三季度增长17.9%调整后营业利润率为14.6%同比收缩171个基点 [6] - 2024年第三季度末现金及现金等价物为7.64亿美元较第二季度末的2.71亿美元增加 [7] - 2024年第三季度末经营活动累计净现金为8.7亿美元较2023年同期的7.45亿美元增加 [7] - 公司有7.77%的五年年化股息增长率 [8] 公司2024年展望 - 公司提供了2024年全年更新指引更新指引包含近期收购（如LifeLabs）和飓风米尔顿影响预计飓风将使四季度净营收减少近1500万美元每股收益减少约8美分 [9] - 全年营收预计在98.0亿 - 98.5亿美元区间（之前为95.0亿 - 95.8亿美元）同比增长5.9% - 6.5%（之前为1.6% - 2.5%）Zacks共识预期为96.3亿美元 [10] - 调整后每股收益预计在8.85 - 8.95美元区间（之前为8.80 - 9.00美元）Zacks对该指标的共识预期为8.89美元 [11] 公司近期估计趋势与评分 - 过去一个月投资者见证了估计审查的下降趋势 [12] - 目前公司增长分数为F动量分数为D价值方面评级为B整体VGM分数为D [13] - 股票估计总体呈下降趋势修正幅度表明向下转变公司Zacks排名为3（持有）预计未来几个月股票回报符合预期 [14]

Quest Diagnostics (DGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of ...

Quest Diagnostics Inc.’s (DGX) robust Advanced Diagnostics offering is poised to drive its growth in the upcoming quarters. Strength in the company’s core business is highly encouraging. Additionally, a strong focus on cost discipline bodes well for the stock. However, mounting debt and lower COVID-19 revenues are concerns for Quest Diagnostics’ operations.In the past year, this Zacks Rank #2 (Buy) stock has increased 20.8% compared with the industry’s 29.4% growth and 33.7% growth of the S&P 500 composite. ...

Quest Diagnostics Inc.’s (DGX) third-quarter revenue growth can be attributed to the strong momentum in its expanding portfolio of Advanced Services. The company strategically deploys AI and automation to improve its operational quality and efficiency. Its base business volume remains robust, which is highly encouraging. However, the mounting debt burden on DGX’s balance sheet could pose challenges for its operations.In the past year, this Zacks Rank #2 (Buy) company’s shares have risen 12.7% compared with ...

Quest Diagnostics (NYSE: DGX ) is a provider of medical diagnostic services to markets across the world. Operations are focused on North America, where DGX has more than 2,000 locations. DGX has extensive coverage over the USBuildingBenjamins is a free stock picking and market commentary investment newsletter. Building Benjamins is the DBA (doing businesses as) publishing entity for Tradition Investment Management, LLC, a registered investment adviser. Benjamin Halliburton, our founder, also founded Traditi ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.In my previous Quest Diagnostics (NYSE: DGX ) article , I analyzed the company’s Q2 2024 earnings report, which produced a beat on EPS and revenue. The company did report that their base business revenue grew almostHe is the leader of the investing group ...